<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Intern Med</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">2168-6106</issn><issn pub-type="epub">2168-6114</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11184500</article-id><article-id pub-id-type="pmcid-ver">PMC11184500.1</article-id><article-id pub-id-type="pmcaid">11184500</article-id><article-id pub-id-type="pmcaiid">11184500</article-id><article-id pub-id-type="pmid">38884975</article-id><article-id pub-id-type="doi">10.1001/jamainternmed.2024.1733</article-id><article-id pub-id-type="publisher-id">ioi240032</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="featured" specific-use="electronic"><subject>Featured</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group></article-categories><title-group><article-title>Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose</article-title><alt-title alt-title-type="headline">Overdose, Behavioral Health Services, and MOUD After a Nonfatal Overdose</alt-title><alt-title alt-title-type="running-head">Overdose, Behavioral Health Services, and MOUD After a Nonfatal Overdose</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jones</surname><given-names initials="CM">Christopher M.</given-names></name><degrees>PharmD</degrees><degrees>DrPH</degrees><xref rid="ioi240032aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shoff</surname><given-names initials="C">Carla</given-names></name><degrees>PhD</degrees><xref rid="ioi240032aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blanco</surname><given-names initials="C">Carlos</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="ioi240032aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Losby</surname><given-names initials="JL">Jan L.</given-names></name><degrees>PhD</degrees><degrees>MSW</degrees><xref rid="ioi240032aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ling</surname><given-names initials="SM">Shari M.</given-names></name><degrees>MD</degrees><xref rid="ioi240032aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Compton</surname><given-names initials="WM">Wilson M.</given-names></name><degrees>MD</degrees><degrees>MPE</degrees><xref rid="ioi240032aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="ioi240032aff1"><label>1</label>Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration, Rockville, Maryland</aff><aff id="ioi240032aff2"><label>2</label>Office of the Administrator, Centers for Medicare &amp; Medicaid Services, Baltimore, Maryland</aff><aff id="ioi240032aff3"><label>3</label>National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland</aff><aff id="ioi240032aff4"><label>4</label>National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia</aff><aff id="ioi240032aff5"><label>5</label>Center for Clinical Standards and Quality, Centers for Medicare &amp; Medicaid Services, Baltimore, Maryland</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> March 28, 2024.</p><p content-type="published-online"><bold>Published Online:</bold> June 17, 2024. doi:<uri content-type="doi">10.1001/jamainternmed.2024.1733</uri></p><corresp id="ioi240032cor1"><bold>Corresponding Author:</bold> Christopher M. Jones, PharmD, DrPH, Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration, 5600 Fishers Ln, Rockville, MD 20857 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="christopher.jones@samhsa.hhs.gov">christopher.jones@samhsa.hhs.gov</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Jones and Shoff had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Ling and Compton share senior authorship.</p><p><italic toggle="yes">Concept and design:</italic> Jones, Shoff, Losby, Compton.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Jones, Shoff, Blanco, Ling, Compton.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Jones, Shoff.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Jones, Blanco, Losby, Ling, Compton.</p><p><italic toggle="yes">Statistical analysis:</italic> Jones, Shoff.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Compton.</p><p><italic toggle="yes">Supervision:</italic> Jones, Compton.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Compton reported long-term stock holdings with General Electric Co, 3M Companies, and Pfizer Inc outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was sponsored by the National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention, the Centers for Medicare &amp; Medicaid Services, the National Institute on Drug Abuse of the National Institutes of Health, and the Substance Abuse and Mental Health Services Administration.</p><p><bold>Role of the Funder/Sponsor:</bold> The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Disclaimer:</bold> The findings and conclusions of this study are those of the authors and do not necessarily reflect the views of the National Institutes of Health, the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Services Administration, the Centers for Medicare &amp; Medicaid Services, or the US Department of Health and Human Services.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-IOI240032-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2024-06-17T10:00"><day>17</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2024</year></pub-date><volume>184</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">465052</issue-id><fpage>954</fpage><lpage>962</lpage><history><date date-type="received"><day>27</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>3</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>17</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-17 00:25:23.430"><day>17</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2024 American Medical Association. All Rights Reserved.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamainternmed-e241733.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamainternmed-e241733.pdf">jamainternmed-e241733.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archinte/fullarticle/10.1001/jamainternmed.2024.1733"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study evaluates access to medications for opioid use disorder (MOUD), naloxone, and behavioral health care and their association with decreased fatal overdose risk among Medicare beneficiaries with recent nonfatal overdose experience.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-ioi240032-1"><title>Question</title><p>During the 12 months after a nonfatal drug overdose, what percentage of Medicare beneficiaries receive medications for opioid use disorder (MOUD), naloxone, or behavioral health services, what percentage have a subsequent nonfatal or fatal drug overdose, and how does receipt of these services affect fatal drug overdose risk?</p></sec><sec id="ab-ioi240032-2"><title>Findings</title><p>In this cohort study of 136 762 Medicare beneficiaries with an index nonfatal drug overdose, subsequent nonfatal and fatal drug overdoses were observed. Subsequent nonfatal drug overdose and an opioid use disorder diagnostic code were associated with increased risk for fatal drug overdose, whereas receipt of a naloxone prescription, methadone, or buprenorphine treatment for opioid use disorder as well as behavioral health services were associated with decreased risk.</p></sec><sec id="ab-ioi240032-3"><title>Meaning</title><p>Findings of this study suggest the need to improve access to behavioral health services; MOUD; and overdose-prevention strategies, such as prescribing naloxone and linking individuals to community-based health care settings for ongoing care.</p></sec></abstract><abstract><sec id="ab-ioi240032-4"><title>Importance</title><p>Recognizing and providing services to individuals at highest risk for drug overdose are paramount to addressing the drug overdose crisis.</p></sec><sec id="ab-ioi240032-5"><title>Objective</title><p>To examine receipt of medications for opioid use disorder (MOUD), naloxone, and behavioral health services in the 12 months after an index nonfatal drug overdose and the association between receipt of these interventions and fatal drug overdose.</p></sec><sec id="ab-ioi240032-6"><title>Design, Setting, and Participants</title><p>This cohort study was conducted in the US from January 2020 to December 2021 using claims, demographic, mortality, and other data from the Centers for Medicare &amp; Medicaid Services, the Centers for Disease Control and Prevention, and other sources. The cohort comprised Medicare fee-for-service beneficiaries aged 18 years or older with <italic toggle="yes">International Statistical Classification of Diseases, Tenth Revision, Clinical Modification</italic> codes for a nonfatal drug overdose. Data analysis was performed from February to November 2023.</p></sec><sec id="ab-ioi240032-7"><title>Exposures</title><p>Demographic and clinical characteristics, substance use disorder, and psychiatric comorbidities.</p></sec><sec id="ab-ioi240032-8"><title>Main Outcomes and Measures</title><p>Receipt of MOUD, naloxone, and behavioral health services as well as subsequent nonfatal and fatal drug overdoses.</p></sec><sec id="ab-ioi240032-9"><title>Results</title><p>The cohort consisted of 136&#8201;762 Medicare beneficiaries (80&#8201;140 females [58.6%]; mean (SD) age of 68.2 [15.0] years) who experienced an index nonfatal drug overdose in 2020. The majority of individuals had Hispanic (5.8%), non-Hispanic Black (10.9%), and non-Hispanic White (78.8%) race and ethnicity and lived in metropolitan areas (78.9%). In the 12 months after their index nonfatal drug overdose, 23&#8201;815 beneficiaries (17.4%) experienced at least 1 subsequent nonfatal drug overdose and 1323 (1.0%) died of a fatal drug overdose. Opioids were involved in 72.2% of fatal drug overdoses. Among the cohort, 5556 (4.1%) received any MOUD and 8530 (6.2%) filled a naloxone prescription in the 12 months after the index nonfatal drug overdose. Filling a naloxone prescription (adjusted odds ratio [AOR], 0.70; 95% CI, 0.56-0.89), each percentage of days receiving methadone (AOR, 0.98; 95% CI, 0.98-0.99) or buprenorphine (AOR, 0.99; 95% CI, 0.98-0.99), and receiving behavioral health assessment or crisis services (AOR, 0.25; 95% CI, 0.22-0.28) were all associated with reduced adjusted odds of fatal drug overdose in the 12 months after the index nonfatal drug overdose.</p></sec><sec id="ab-ioi240032-10"><title>Conclusions and Relevance</title><p>This cohort study found that, despite their known association with reduced risk of a fatal drug overdose, only a small percentage of Medicare beneficiaries received MOUD or filled a naloxone prescription in the 12 months after a nonfatal drug overdose. Efforts to improve access to behavioral health services; MOUD; and overdose-prevention strategies, such as prescribing naloxone and linking individuals to community-based health care settings for ongoing care, are needed.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>